



Market Announcement

25 November 2024

Island Pharmaceuticals Limited (ASX: ILA) – Trading Halt

Description

The securities of Island Pharmaceuticals Limited ('ILA') will be placed in trading halt at the request of ILA, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 27 November 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

25 November 2024

Ms Melissa Kostopoulos
Adviser, Listings Compliance
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
MELBOURNE VIC 3000

By email: Melissa.Kostopoulos@asx.com.au

Dear Ms Kostopoulos

Island Pharmaceuticals Ltd (ASX:ILA) (Island Pharmaceuticals/Company) – Request for Trading Halt

Island Pharmaceuticals requests a halt to the trading in its ordinary shares quoted on the Australian Securities Exchange (**ASX**) with effect from prior to commencement of trading today, 25 November 2024.

In accordance with ASX Listing Rule 17.1, Island Pharmaceuticals provides the following information in relation to the request:

- (a) The trading halt is requested pending an announcement by Island Pharmaceuticals in relation to the Safety Review Committee 'SRC' recommendation regarding the Phase 2a cohort of the PROTECT study.
- (b) Island Pharmaceuticals requests that the trading halt remain in place until the earlier of open trade on 27 November 2024 or the release of an announcement by the Company in relation to the Safety Review Committee 'SRC' recommendation regarding the Phase 2a cohort of the PROTECT study.
- (c) Island Pharmaceuticals is seeking the trading halt to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the Company's shares.

Island Pharmaceuticals confirms that it is not aware of any reason why the trading halt should not be granted and is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely



Cameron Jones
CFO and Company Secretary

Approved by Phillip Lynch, Executive Chair and David Foster, CEO and Managing Director.